...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Zenith Q4 2017 Events
4
Nov 07, 2017 10:13AM
5
Nov 12, 2017 05:05PM
3
Nov 13, 2017 10:30AM

Lets see if that  expected PP is for $3.3 million shares plues a warrant for $10 Mil  or  10,000,000 shares plus a warrant( my guess)$1 cad share value  or even better

2,600,000 shares based on the $3USD  share enterprise value(last presentaion), worth  $3usd if someone or co thinks its worth that,

would rather see an IPO or buyout talked about years ago, 

 

Share
New Message
Please login to post a reply